Cvrx, Inc. Stock Price, News & Analysis

CVRx (NASDAQ: CVRX) reported its Q2 2025 financial results, achieving total revenue of $13.6 million, up 15% year-over-year. The company's U.S. Heart Failure revenue reached $12.1 million, also growing 15%. Active U.S. implanting centers increased 27% to 240 centers.

Key developments include CMS's proposal to maintain Barostim in APC 1580 for 2026 with a $45,000 outpatient procedure payment, favorable physician fee proposals for Category I CPT codes, and the appointment of Brent Binkowski as COO. The company narrowed its FY2025 guidance to $55.0-$57.0 million in revenue with 83-84% gross margin.

Despite revenue growth, CVRx reported a net loss of $14.7 million ($0.57 per share) and held $95.0 million in cash and equivalents as of June 30, 2025.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 3:00 PM ET.

Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close.

The company will host a conference call at 4:30 PM Eastern Time to discuss the results. Investors can access the call via telephone using the conference ID CVRXQ225 or through a live webcast available on the company's investor relations website at ir.cvrx.com.

[]

CVRx (NASDAQ: CVRX) announced that CMS has proposed to maintain Barostim implant procedures in the New Technology APC 1580, with an approximate payment of $45,000 for outpatient procedures. This follows two significant reimbursement developments: Barostim's assignment to a higher-paying MS-DRG for inpatient procedures (October 2024) and its transition from Category III to Category I CPT codes for physician payments (effective January 2026).

The final 2026 Medicare Hospital OPPS rule is expected in November 2025, with implementation planned for January 2026. These reimbursement updates validate Barostim's clinical value in treating heart failure patients with reduced ejection fraction.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The company's management team is scheduled to present on June 4, 2025, at 10:00am Central Time. Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.

CVRx reported its Q1 2025 financial results with total revenue of $12.3 million, up 15% year-over-year. U.S. Heart Failure revenue reached $11.1 million, a 14% increase. The company expanded its U.S. presence to 227 active implanting centers, a 19% growth since March 31, 2024. Notable achievements include compelling real-world evidence showing Barostim's effectiveness, with an 85% reduction in heart failure hospital visits. However, financial challenges persist with a net loss of $13.8 million ($0.53 per share). The company updated its 2025 guidance, projecting total revenue between $55-58 million. CVRx maintains strong liquidity with $102.7 million in cash and cash equivalents, while continuing to invest in commercial expansion despite revenue growth not meeting expectations.

CVRx (NASDAQ: CVRX), a commercial-stage medical device company, has scheduled the release of its first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The company will host a conference call and live webcast at 4:30pm Eastern Time to discuss the results.

Investors can access the webcast through the company's investor relations website at ir.cvrx.com. For telephone participation, U.S. callers should dial 1-800-445-7795, while international callers can use 1-785-424-1699. The conference ID for the call is CVRXQ125.

CVRx (NASDAQ: CVRX) announced preliminary Q1 2025 revenue of approximately $12.3 million, showing 15% growth compared to Q1 2024's $10.8 million. The revenue comprises $11.2 million from U.S. operations and $1.1 million from European operations.

Despite growth, revenue fell short of expectations due to seasonal softness and newer sales representatives still developing their territories. The company's U.S. presence includes 227 active implanting centers, up from 223 in December 2024, while sales territories decreased by 3 to 45.

The company's cash position stands at $102.7 million. During Q1 2025, CVRx issued 543,462 shares through an at-the-market offering, raising $9.5 million in gross proceeds.

CVRx (NASDAQ: CVRX) presented new real-world evidence at THT 2025 demonstrating significant reductions in healthcare utilization with Barostim for heart failure patients. The study, published in the Journal of Cardiac Failure, analyzed data from 306 Barostim patients using the Premier Healthcare Database.

The analysis compared 12 months pre-implant data with almost two years post-implant (1.92±1.87 years), revealing remarkable reductions in hospital visits:

• 86% reduction in all-cause hospital visits
• 84% reduction in cardiovascular hospital visits
• 85% reduction in heart-failure hospital visits

All results were statistically significant (p0.0001). The study also found significant reductions in length of hospital stays, providing important evidence for clinicians and payers considering the device for their patients.